(Q40235023)

18 September 2017

Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells (English)

1 reference

18 September 2017

1 reference

3

David C Linch

1 reference

18 September 2017

Victoria L Grandage

1

1 reference

18 September 2017

Tamara Everington

series ordinal

2

1 reference

18 September 2017

Asim Khwaja

series ordinal

4

1 reference

18 September 2017

language of work or name

English

0 references

publication date

4 September 2006

1 reference

British Journal of Haematology

18 September 2017

1 reference

18 September 2017

135

1 reference

18 September 2017

303-316

1 reference

18 September 2017

3

1 reference

Characterization of apoptosis induced by protein kinase C inhibitors and its modulation by the caspase pathway in acute promyelocytic leukaemia

18 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

The effect of chemical blockade of PKC with Gö6976 and Gö6983 on proliferation and MAPK activity in IL-6-dependent plasmacytoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

The Janus protein tyrosine kinases in hematopoietic cytokine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Protein kinase inhibitors: the tyrosine-specific protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Dual tyrosine kinase inhibitors in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Determination of the transphosphorylation sites of Jak2 kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Cytokine signaling in 2002: new surprises in the Jak/Stat pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Constitutive activation of STAT transcription factors in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

The role of signal transducer and activator of transcription factors in leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Polycythemia vera: scientific advances and current practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06291.X

10.1111/J.1365-2141.2006.06291.X

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference